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Abstract
Background: Hyperparathyroidism in humans and continuous parathyroid hormone (cPTH) treatment in mice cause bone
loss by regulating the production of RANKL and OPG by stromal cells (SCs) and osteoblasts (OBs). Recently, it has been
reported that T cells are required for cPTH to induce bone loss as the binding of the T cell costimulatory molecule CD40L to
SC receptor CD40 augments SC sensitivity to cPTH. However it is unknown whether direct PTH stimulation of T cells is
required for cPTH to induce bone loss, and whether T cells contribute to the bone catabolic activity of PTH with mechanisms
other than induction of CD40 signaling in SCs.
Methodology/Principal Findings: Here we show that silencing of PTH receptor 1 (PPR) in T cells blocks the bone loss and
the osteoclastic expansion induced by cPTH, thus demonstrating that PPR signaling in T cells is central for PTH-induced
reduction of bone mass. Mechanistic studies revealed that PTH activation of the T cell PPR stimulates T cell production of
the osteoclastogenic cytokine tumor necrosis factor a (TNF). Attesting to the relevance of this effect, disruption of T cell TNF
production prevents PTH-induced bone loss. We also show that a novel mechanism by which TNF mediates PTH induced
osteoclast formation is upregulation of CD40 expression in SCs, which increases their RANKL/OPG production ratio.
Conclusions/Significance: These findings demonstrate that PPR signaling in T cells plays an essential role in PTH induced
bone loss by promoting T cell production of TNF. A previously unknown effect of TNF is to increase SC expression of CD40,
which in turn increases SC osteoclastogenic activity by upregulating their RANKL/OPG production ratio. PPR-dependent
stimulation of TNF production by T cells and the resulting TNF regulation of CD40 signaling in SCs are potential new
therapeutic targets for the bone loss of hyperparathyroidism.
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Introduction
Parathyroid hormone (PTH) is a major regulator of calcium
metabolism which defends against hypocalcemia, in part by
stimulating bone resorption and thereby the release of calcium
from the skeleton. Chronic overproduction of PTH is a cause of
skeletal and extra-skeletal disease. Secondary hyperparathyroidism
has been implicated in the pathogenesis of senile osteoporosis [1],
while primary hyperparathyroidism (PHP), is associated with
accelerated bone loss [2], osteopenia [3,4,5], and increased bone
turnover [3], an independent risk factor for fractures. Further-
more, PHP is a cause of extra-skeletal manifestations stemming
from increased bone resorption such as hypercalcemia, recurrent
nephrolithiasis, renal failure, and mental changes [4].
PHP and secondary hyperparathyroidism are mimicked by
cPTH infusion. By contrast, daily injections of PTH, a regimen
known as intermittent PTH (iPTH) treatment, cause a marked
stimulation of bone formation and increase bone strength [6]. As a
result, iPTH is an approved treatment modality for osteoporosis
[7].
Hyperparathyroidism and cPTH treatment cause cortical bone
loss by enhancing endosteal resorption through stimulation of
osteoclast (OC) formation and activity [4,8,9], and often lead to
trabecular bone loss [4,8], although mild PHP and cPTH
treatment of young mice may induce a modest increase in
cancellous bone [3,5,10,11]. Hyperparathyroidism and cPTH
treatment increase bone turnover in trabecular and cortical bone,
as evidenced by elevations in histomorphometric and biochemical
markers of resorption and formation [8,12,13].
The effects of PTH on bone result from its binding to the PTH/
PTH-related protein (PTHrP) receptor (PPR or PTHR1),
expressed on bone marrow (BM) stromal cells (SCs), OBs and
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to be mediated, in part, by enhanced production of receptor
activator of nuclear factor-kB ligand (RANKL) and macrophage
colony stimulating factor (M-CSF), and decreased production of
osteoprotegerin (OPG) by SCs and OBs [16,17]. Furthermore,
additional BM cells contribute to the catabolic activity of PTH in
vivo. Among them are T cells, a lineage that expresses PPR
[18,19,20] and responds to PTH [21,22]. T cells also express
surface receptors that bind to, and activate counter-receptors
found on the surface of cells of the osteoblastic lineage [23]. One of
these osteoblastic cell surface receptors is CD40, which upon
ligation by T cell expressed CD40 ligand (CD40L), provides
survival and proliferative cues to SCs and OBs [23].
A role for T cells in the response to PTH was first suggested by
Hory et al [24], who reported that transplantation of human
parathyroid gland fragments from patients with primary and
secondary hyperparathyroidism into nude mice fails to stimulate
OC formation and bone resorption. We have further reported that
cPTH fails to induce OC formation, bone resorption and cortical
bone loss in mice lacking T cells [11]. We also found that PTH-
induced bone loss is blocked in WT mice by treatment with T cell-
depleting antibodies (mAbs) [11]. Our studies further disclosed the
existence of a cross-talk between T cells and SCs mediated by the
CD40L/CD40 signaling system. T cells expand the pool of BM
SCs and sensitize SCs to PTH through CD40L. As a result, the
absence of T cells or deletion of T cell expressed CD40L blunts the
bone catabolic activity of PTH by decreasing BM SC number,
their RANKL/OPG ratio, and hence their osteoclastogenic
activity [11].
Further studies from our laboratory have also linked T cells to
the bone anabolic activity of iPTH, although the involved
mechanisms are unrelated to CD40L. Treatment with iPTH
increases the CD8+ T cell production of Wnt10b, a Wnt ligand
that stimulates osteoblastogenesis by activating Wnt signaling in
SCs and OBs. As a result, the bone anabolic activity of iPTH is
markedly reduced in T cell-deficient mice and in mice with a
selective disruption of T cell Wnt10b production [19].
In spite of the growing evidence supporting a role for T cells in
the mechanism of cPTH actions on bone, the mechanisms
involved are only partly understood, as it remains unknown
whether cPTH acts directly on T cells to exert its effects in bone.
Also unknown is whether T cells contribute to the bone catabolic
activity of cPTH via mechanisms other than induction ofCD40
signaling in SCs. To address these issues we have conditionally
silenced PPR in T cells and determined whether PTH activation
of PPR in T cells is required for cPTH to exert its bone catabolic
activity. We show that blocking PPR signaling in T cells abrogates
the capacity of cPTH treatment to stimulate OC formation and
induce bone loss. We further show that PPR signaling in T cells
stimulates the secretion of the osteoclastogenic cytokine TNF, a
factor which promotes OC differentiation and bone resorption
both directly, and by regulating the production of RANKL and
OPG by SCs and OBs. Therefore, direct targeting of T cells by
PTH is required for PTH to induce its bone catabolic effects, and
T cell production of TNF is a novel mechanism by which T cells
contributes to the bone catabolic activity of cPTH.
Results
Generation of PPR
T cells 2/2 mice
To elucidate whether direct stimulation of T cells by cPTH
through PPR signaling is required for cPTH to induce bone loss,
we generated a mouse, referred to herein as PPR
fl/fl/Lck-Cre, or
PPR
T cells 2/2 mouse, with targeted deletion of PPR in ab and
cd T cells. To this end, C57BL/6 mice harboring a PPR allele
with floxed exon E1 (PPR
fl/fl) developed by Kobayashi et al [25]
were crossed with C57BL/6 Lck-Cre transgenic mice, a strain that
expresses the Cre recombinase in the early stages (DN2-DN3) of
thymocyte development [26]. Thus, in the PPR
T cells 2/2 mouse
the PPR gene is silenced in T cell precursors and mature ab and
cd T cells.
PCR Analysis of DNA from BM macrophages (BMMs) and SCs
revealed the presence of a full length PPR gene in all genotypes,
ensuring absence of Cre expression in these cells (Fig. 1a).
Conversely, analysis of T cell DNA revealed that partial or
complete recombination of the PPR gene occurred in PPR
fl/+/
Lck-Cre and PPR
fl/fl/Lck-Cre mice, respectively, due to the
successful deletion of floxed exon E1. Quantitative analysis of PPR
RNA by real time RT-PCR, confirmed deletion (.90%) of the
floxed exon E1 of the PPR gene in spleen CD4+ and CD8+ T cells
from PPR
T cells 2/2 mice, as compared to CD4+ and CD8+ cells
from PPR
fl/fl mice (Fig. 1b). Moreover, in vitro PTH treatment
induced a significant increase in the production of cAMP in spleen
CD4+ and CD8+ T cells from PPR
fl/fl control mice, but not in
those from PPR
T cells2/2 mice (Fig. 1c). These findings
demonstrate that T cell expression of functioning PPR is
specifically blocked in PPR T cells 2/2 mice as a result of
efficient Cre-mediated exon E1 ablation.
At 6 weeks of age PPR
T cells 2/2 mice and control littermates
had no gross skeletal alterations, and similar femoral (bone mineral
density) BMD values. All strains had similar serum levels of
calcium, phosphate and PTH (Figure S1). Moreover, all mice had
comparable numbers of splenic CD4+ and CD8+ T cells, a similar
expression of the activation marker CD25, and comparable T cell
proliferation.
cPTH treatment fails to cause bone loss, stimulate bone
resorption and induce in vitro OC formation in mice
lacking PPR signaling in T cells
Infusion of hPTH 1–34 at the rate of 80 mg/kg/day for 2 weeks,
a treatment modality referred to hereafter as cPTH, models the
steady state elevation of PTH levels characteristic of moderate to
severe PHP [11]. To determine whether PPR signaling in T cells is
required for cPTH to induce bone loss, male PPR
T cells 2/2 and
littermate controls were infused with vehicle or cPTH starting at
16 weeks of age, a time point when C57/BL6 mice reach peak
bone size and mechanical strength [27], and cPTH infusion results
in the loss of cortical and trabecular bone. By contrast, treatment
with cPTH at the age of 10 weeks results in cortical but not
trabecular bone loss [11].
To assess the differential effects of cPTH on cortical and
trabecular bone, micro-computed tomography (mCT) was utilized
to analyze femurs harvested at sacrifice. All groups of vehicle
treated mice had similar values of cortical thickness and cortical
volume. Treatment with cPTH induced significant cortical
thinning and loss of cortical volume in PPR
fl/fl mice (Fig. 2a,b).
In contrast, cPTH did not cause significant cortical bone loss in
heterozygous PPR
fl/+/Lck-Cre and homozygous PPR
T cells 2/2
mice. Vehicle treated PPR
fl/+/Lck-Cre and PPR
T cells 2/2 mice
had lower BV/TV as compared to vehicle treated PPR
fl/fl mice,
suggesting that PPR signaling in T cells may contribute to the
anabolic activity of endogenous PTH. Treatment with cPTH
led to a significant decrease in trabecular BV/TV in PPR
fl/fl mice
but not in PPR
fl/+/Lck-Cre mice. Strickingly, treatment of
PPR
T cells 2/2 mice with cPTH resulted in a significant increase
in BV/TV (Fig. 2c).
Measurements of serum C-terminal telopeptide of collagen
(CTX), a biochemical marker of resorption, revealed that cPTH
T Cell PTH Receptor
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fl/fl mice,
but not in PPR
fl/+/Lck-Cre and PPR
T cells 2/2 mice (Fig. 2d).
Assessment of osteocalcin (OCN) levels, a marker of bone
formation, showed that serum osteocalcin was equally increased
by cPTH in all groups (Fig. 2e).
Histomorphometric analysis of femoral trabecular bone revealed
that the number of OCs per bone surface (NOc/BS) and the OC
surface per bone surface (Oc.S/BS), two indices of bone resorption,
wereincreasedbycPTHtoagreateramountincontrolmicethanin
PPR
T cells 2/2 mice (Fig. 2f,g). In contrast, bone formation rate
(BFR/BS), mineral apposition rate (MAR), the numbers of OBs per
bone surface (N.Ob/BS), and the percent of bone surface covered
by OBs (Ob.S/BS), which are indices of bone formation, were
significantly augmented by cPTH in all groups (Fig. 2h–k). The
changes in the percentage of mineralized surface, another index of
bone formation, did not reach statistical significance in any of the
groups (Fig. 2l). Thus, while PPR signaling in T cells is required for
cPTH to induce bone loss and stimulate bone resorption, it is not
required for cPTH to stimulate bone formation. To exclude the
possibility of a sexually dimorphic role of PPR signaling in T cells,
a second experiment was conducted using female mice of 16
weeks of age. Treatment with cPTH induced significant cortical
and trabecular bone loss in PPR
fl/fl, while it had no effect in
PPR
T cells 2/2 mice (Figure S2). Mirroring the effects induced on
bone volume, cPTH caused an increase in histomorphometric and
biochemical indices of bone resorption in PPR
fl/fl and PPR
fl/+/Lck-
Cre mice, but not in PPR
T cells 2/2 mice. In contrast, cPTH
increased histomorphometric and biochemical indices of bone
formationinallstrains.Thus,PPRsignalinginTcellsisrequiredfor
cPTH to cause bone loss in male and female mice.
Ovariectomy (ovx) and cPTH are known to have additive bone
catabolic effects, and previous studied from our laboratory have
implicated T cells in the mechanism of ovx induced bone loss [28].
We thus investigated whether silencing of PPR in T cells prevents
bone loss in mice subjected to ovx and cPTH treatment. In vivo
measurements of femoral BMD by (Dual X-ray Absorptiometry)
DEXA revealed that ovx causes equal bone loss in vehicle treated
PPR
Tcells 2/2 and control mice. Measurements DEXA and mCT
further revealed that ovx PPR
fl/fl mice treated with cPTH
sustained a greater cortical and trabecular bone loss than ovx
PPR
fl/fl mice treated with vehicle. By contrast cPTH did not
induce significant further bone loss in ovx PPR
T cells 2/2 mice
(Figure S3), thus confirming that PPR signaling in T cells plays a
critical role in the mechanism of action of cPTH.
Figure 1. Confirmation of PPR gene disruption in PPR
T cells 2/2 mice. A Characterization of floxed and Cre recombined PPR alleles in BMMs,
SCs and T cells from PPR
T cells 2/2 and control mice. B PPR mRNA levels (Mean 6 SEM) in CD4+ and CD8+ T cells from PPR
T cells 2/2 and control
mice. *=p,0.05 and **=p,0.01 compared to the corresponding PPR
fl/fl group. C Effect (Mean 6 SEM) of in vitro PTH treatment (50 nM) on cAMP
accumulation by splenic CD4+ and CD8+ T cells from PPR
T cells 2/2 and control mice. *=p,0.05 and **=p,0.01 compared to the corresponding
vehicle group.
doi:10.1371/journal.pone.0012290.g001
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and osteoclastogenic cytokines in SCs
To establish whether PPR signaling in T cells is required for
PTH to induce OC formation in vitro, we counted the number of
OCs produced by osteoclastogenic cultures of whole BM. In vitro
PTH treatment caused a smaller increase in OC number in BM
derived from PPR
T cells 2/2 mice, as compared to BM from
control mice (Fig. 3a).
To investigate the responsible mechanism, BMMs from
PPR
T cells 2/2 and control mice were cultured with RANKL
and M-CSF for 7 days and OCs counted. These experiments
revealed that BMMs from all genotypes generated the same
number of OCs (not shown), thus excluding that silencing of PPR
in T cells alters the osteoclastogenic potentials of BMMs.
We have reported that T cells potentiate PTH-induced
osteoclastogenesis mainly by increasing the osteoclastogenic
activity of BM SCs [11]. Thus, silencing of PPR signaling in T
cells may blunt PTH-induced osteoclastogenesis by decreasing the
capacity of SCs to support OC formation. To investigate this
hypothesis, BMMs from intact WT mice were cultured for 7 days
with SCs from either PPR
T cells 2/2 or control mice in the
presence of PTH, a hormone that under these conditions
promotes OC formation by targeting SCs. Cocultures containing
SCs from PPR
T cells 2/2 mice produced fewer OCs, as compared
to those with SCs from control mice (Fig. 3b), suggesting that the
lack of PPR signaling in T cells leads to the emergence of SCs
characterized by blunted sensitivity to PTH. To investigate the
responsible mechanism, SCs were harvested from PPR
T cells 2/2
and control mice treated with vehicle or cPTH for 2 weeks and
their production of cytokine mRNA assessed by RT-PCR. This
analysis revealed that cPTH increased the expression of RANKL
mRNA and lowered that of OPG mRNA in SCs from control
mice but not in those from PPR
T cells 2/2 mice (Fig. 3c), thus
indicating that one mechanism by which PPR signaling in T cells
increases SC osteoclastogenic activity is by regulating their
production of osteoclastogenic cytokines.
Silencing of PPR signaling in T cells did not alter the capacity
of SCs to differentiate into OBs because SC from control and
PPR
T cells 2/2 mice exhibited the same capacity to form colony
forming unit-alkaline phosphatase (CFU-ALP) and bone nodules
in vitro (Figure S4).
Induction of CD40 signaling in SCs by T cell-expressed CD40L
is a key mechanism by which T cells sensitize SCs to PTH [11].
An important element of this regulatory loop is the capacity of
PTH to upregulate the expression of CD40 in SC from T cell
replete mice but not from T cell deficient mice [11]. This suggests
that PTH regulates CD40 expression on SCs through T cells.
Therefore, silencing of PPR signaling in T cells may blunt the
osteoclastogenic activity of SCs by blocking the stimulatory effect
of cPTH on CD40 expression in SCs. To investigate this
hypothesis SCs were harvested from PPR
T cells 2/2 and control
mice treated with vehicle or cPTH for 2 weeks and analyzed for
CD40 and cytokine mRNA expression by RT-PCR. Treatment
with cPTH upregulated the mRNA levels of CD40 in SCs from
PPR
fl/fl mice, but not in SCs from PPR
T cells 2/2 mice (Fig. 3d).
Confirming findings from our earlier reports [11], additional
studies revealed that cPTH does not upregulate the expression of
CD40L in T cells (not shown). Together, these findings suggest
that one mechanism by which PPR signaling in T cells augments
the osteoclastogenic activity of SCs is by upregulating their
expression of CD40.
Having established that PPR signaling in T cells is required for
PTH to upregulate CD40 expression in SCs, we investigated
whether activation of the CD40 receptor by CD40L potentiates
the SC response to PTH. To this end, WT SCs were stimulated by
PTH alone or with soluble CD40L and PTH, and assayed for
phosphorylated extracellular signal regulated mitogen-activated
protein kinases 1 and 2 (ERK1/2), which are activated by PPR
signaling. Western blot analysis revealed that combined stimula-
tion with CD40L and PTH induced a ,4 fold higher increase in
the levels of phosphorylated ERK2 than treatment with PTH or
CD40L alone (Figure S5). These findings demonstrate that SCs
are synergistically activated by PPR signaling and CD40L, and
attest to the relevance of CD40L/CD40 signaling in regulating the
SC response to PTH.
PPR signaling in T cells causes bone loss through
increased production of TNF
We found that in vitro stimulation of SCs by TNF upregulated
CD40 expression in SCs (Fig. 4a), suggesting that PTH may
upregulate SC expression of CD40 through TNF. To seek in vivo
confirmation, SCs were purified from WT and TNF2/2 mice
after the completion of 2 weeks of treatment with vehicle and
cPTH, and analyzed for CD40 mRNA expression by real time
RT-PCR. These studies revealed that cPTH increased CD40
mRNA levels by ,2 folds in SCs from WT mice, while it had no
effect in those from TNF2/2 mice (Fig. 4b). Attesting to
specificity, in vitro TNF treatment did not upregulate CD40
expression in BMMs. Moreover, in vivo cPTH treatment did not
upregulate CD40 expression in BMMs from WT and TNF2/2
mice (not shown).
To determine whether PTH stimulates T cell production of
TNF, and if it does so via a direct effect on T cells, PPR
T cells 2/2
and control mice were treated with vehicle or cPTH for 2 weeks.
Splenic CD4+ and CD8+ T cells were cultured for 48 hours in
plates coated with anti CD3 and anti CD28 mAbs to induce T cell
activation, and the levels of TNF in the culture media measured by
ELISA. We found that cPTH increased TNF production by CD4+
(Fig. 4c) and CD8+ cells (Fig. 4d) from control mice, while there
was no effect in those from PPR
T cells 2/2 mice.
By contrast, in vivo cPTH treatment did not increase the
production of RANKL by CD4+ and CD8+ cells (not shown).
To determine the role of TNF in the bone loss induced by PTH,
WT and TNF2/2 mice were infused with cPTH for 2 weeks.
Measurements by mCT revealed that cPTH caused cortical bone
loss in WT but not in TNF2/2 mice (Fig. 5a,b). Analysis of
trabecular bone disclosed that BV/TV was significantly decreased
by cPTH in WT mice. By contrast BV/TV was not significantly
Figure 2. Effects of cPTH treatment on indices of bone structure and turnover in PPR
T cells 2/2 and control mice. A. mCT analysis of
femur cortical bone thickness (Co.Th). B. mCT analysis of femur cortical bone volume (Co.Vo). C. mCT analysis of trabecular bone volume (BV/TV). D
Analysis of serum CTX levels by ELISA. E Analysis of serum OCN levels by ELISA. F–L Histomorphometric analysis femoral trabecular bone. F:
percentage of bone surface covered by osteoclasts (Oc.S/BS). G: number of osteoclasts per mm bone surface (N.Oc/BS). H: Bone formation rate (BFR).
I: Mineral Apposition rate (MAR), J: Percentage of bone surface covered by osteoblasts (Ob.S/BS). K: Number of osteoblasts per mm bone surface
(N.Ob/BS). L: percentage of mineralized bone surface (MS/BS). *=p,0.05, **=p,0.01 and ***=p,0.001 compared to the corresponding vehicle
treated group. #=p,0.05 compared to the corresponding PPR
fl/fl mice. n=18–22 mice per group for mCT and serum measurements. n=10–12 mice
per group for bone histomorphometry. Data are means 6 SEM.
doi:10.1371/journal.pone.0012290.g002
T Cell PTH Receptor
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12290T Cell PTH Receptor
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12290affected by cPTH in TNF2/2 mice, although it trended toward
an increase (Fig. 5c). Histomorphometric analysis of femoral
trabecular bone confirmed that the number of OCs per bone
surface (N.Oc/BS) and the OC surface per bone surface (Oc.S/
BS), two indices of bone resorption, were increased by cPTH in
WT but not in TNF 2/2 mice (Fig. 5d,e). By contrast, two
indices of bone formation (N.Ob/BS and Ob.S/BS) were
significantly augmented by cPTH in all groups (Fig. 5f,g), while
a third one, BFR, was increased by iPTH treatment in WT mice
and trended toward an increase in TNF2/2 mice (Fig. 5h).
Together, these data demonstrate that TNF is required for cPTH
to increase bone turnover and cause bone loss.
To confirm that one of the mechanisms by which TNF
contributes to cPTH to induce bone loss is by regulating the SC
production of osteoclastogenic factors, SCs were purified from the
BM of WT and TNF2/2 mice treated with vehicle or cPTH, and
their mRNA levels of RANKL and OPG were measured by
quantitative real time RT-PCR. This analysis revealed that cPTH
increased the expression of RANKL mRNA (Fig. 5i) and lowered
that of OPG mRNA (Fig. 5j) in SCs from WT mice but not in
those from TNF2/2 mice.
To investigate the specific contribution of T cell produced TNF to
the bone loss induced by cPTH, nude mice were subjected to adoptive
transfer of T cells purified from the spleen of WT or TNF 2/2 mice
using established methods [11,19,29]. After 2 weeks, a length of time
sufficient for the engraftment and the homeostatic expansion of donor
T cells [11,29], the reconstituted mice were treated with cPTH for 2
w e e k s .C o n t r o li n c l u d e dW Tm i c ea n dTc e l ld e f i c i e n tn u d em i c e .
Measurements of cortical and trabecular bone structure by mCT, and
of biochemical indices of bone turnover revealed that cPTH caused
cortical and trabecular bone loss,and an increase in serum CTX levels
in WT mice and in nude mice reconstituted with WT T cells. In
contrast cPTH did not induce significant changes in any of these
indices in T cell deficient nude mice, or nude mice adoptively
transferred with T cells from TNF2/2 m i c e( F i g .6 a – d ) .H o w e v e r ,
cPTH caused a similar increase in serum osteocalcin levels in all
groups (Fig. 6e). These findings demonstrate that T cell produced
TNF plays a pivotal role in the bone loss and the stimulation of bone
resorption induced by cPTH.
Discussion
We report that mice lacking PPR signaling in T cells are
protected against the loss of cortical and trabecular bone induced
by cPTH. PPR signaling in T cells is relevant as it increases T cell
production of TNF, an osteoclastogenic factor which promotes
OC formation through multiple mechanisms, including direct
stimulation of maturing OC precursors. In addition, T cell
produced TNF augments the sensitivity of SCs to cPTH by
upregulating their expression of CD40 (Fig. 7). These findings
demonstrate that T cells are a direct target of cPTH which plays a
pivotal role in the osteoclastogenic response to cPTH.
Three receptors for PTH have been described. The species that
mediates the effects of PTH in bone is the PTH/PTHrP receptor
(PPR or PTHR1), a member of a seven transmembrane-spanning
domain receptor family, the G-protein coupled receptors
[13,14,15]. An alternative PTH receptor is PTHR2, a protein
expressed primarily in the central nervous system and the
cardiovascular system, which is not known to play a role in bone
[30,31,32]. Recently, a receptor specific for the carboxyl terminal
PTH fragments has been proposed and is yet to be cloned [33].
The function of this receptor in bone is unknown but not relevant
for the effects of PTH1-34.
We have reported that PPR mRNA is expressed in T cells and
that in vitro PTH treatment increases cAMP accumulation in
CD4+ and CD8+ T cells [19]. Stemming from this evidence and
from the finding that the catabolic activity of cPTH is blunted in T
cell-deficient mice [11], we hypothesized that T cells contribute to
the bone catabolic effects of cPTH as a result of PTH binding to
the PPR in T cells. To investigate this hypothesis, we genetically
disrupted the PPR gene in T cells by targeted deletion of exon E1
of PPR using Cre-LoxP technology. Crossing of mice expressing
an exon E1-floxed PPR allele [25] with mice that express Cre
recombinase under the control of the T cell-specific promoter Lck
[26], led to the generation of mice with disrupted PPR gene in T
cells (PPR
T cells 2/2 mice), and intact PPR expression in other
cells. The efficient and specific deletion of exon E1 of PPR in T
cells was established by demonstrating a reduced exon 1-containig
PPR mRNA expression in T cells from PPR
T cells 2/2 mice. The
impact of PPR gene disruption on PPR function was further
assessed by demonstrating attenuated PTH increased cAMP
accumulation in isolated PPR
T cells 2/2 compared to controls.
At 6 weeks of age mice lacking PPR signaling in T cells have a
normal bone phenotype, and normal serum calcium, phosphate
and PTH levels, indicating that PPR signaling in T cells does not
play a major role in bone modeling and baseline remodeling.
However, at 18 weeks of age mice lacking functional PPR in T
cells displayed lower BV/TV values than PPR
fl/fl mice, suggesting
that PPR signaling in T cells contributes to the bone anabolic
activity of endogenous PTH. Alternatively, the data may suggest
that baseline PPR signaling per se provides bone anabolic signals
that become relevant for optimal skeletal growth. Moreover,
PPR
T cells 2/2 mice have a normal number of T cells that exhibit
a degree of activation and proliferation similar to control T cells.
However, when challenged with cPTH, PPR
T cells 2/2 mice are
protected against the loss of cortical and trabecular bone observed
in control mice. The resistance to cPTH-induced bone loss in
PPR
T cells 2/2 mice can be explained by the reduced capacity of
cPTH to stimulate bone resorption and expand the pool of
resorbing OCs. Silencing of PPR signaling in T cells modified the
effects of cPTH on trabecular bone from a net bone loss in control
mice to bone gain in the PPR
T cells 2/2 mice. This bone gain,
which is attributed to the ability of cPTH to retain its capacity to
stimulate bone formation in spite of diminished resorption, is in
agreement with our previous report that cPTH effects on bone
formation were preserved despite the absence of T cells [11].
Consistent with the hypothesis that cPTH stimulates bone
formation through a T cell independent mechanism, is the report
Figure 3. PTH effects on OC formation, SC osteoclastogenic activity and SC RANKL, OPG, and CD40 expression. A. Images of in vitro
PTH treated BM stained for TRAP to visualize OCs (top panel), and number of OCs per well (bottom panel). BM from PPR
Tcells2/2 and control mice
were stimulated with PTH (1 nM) for 7 days, stained for TRAP, and OCs counted. **=p,0.01 and ***=p,0.001 compared to vehicle. #=p,0.05
compared to the other PTH treated groups. B WT BMMs were cocultured with SCs isolated from PPR
T cells 2/2 and control mice treated in vivo with
cPTH or vehicle. Cells were cultured for 7 days in the presence of PTH (1 nM), stained for TRAP, and OCs counted. **=p,0.01 and ***=p,0.001
compared to vehicle. #=p,0.05 compared to the other PTH treated groups. C. mRNA levels of RANKL and OPG in SCs from PPR
T cells 2/2 and
control mice treated in vivo with vehicle or cPTH. *=p,0.05 and **=p,0.01 compared to the corresponding vehicle treated group. D mRNA levels
of CD40 in SCs from PPR
T cells 2/2 and control mice treated in vivo with vehicle or cPTH. *=p,0.05 compared to the corresponding vehicle treated
group. Data are Means + SEM.
doi:10.1371/journal.pone.0012290.g003
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whose production is suppressed by cPTH [34], plays a central role
in the mechanism by which continuous PPR activation increases
bone formation [35]. It should be noted however that contrary to
cPTH, iPTH treatment stimulates bone formation only in the
presence of T cells [19]. This striking difference can be explained,
at least in part, by the specific capacity of iPTH to increase T cell
production of Wnt10b [19], a Wnt ligand that stimulates
osteoblastogenesis and blocks OB apoptosis by activating Wnt
signaling in OBs [36].
Deletion of CD40L in T cells, or lack of CD40 in SCs blunts the
bone catabolic activity of cPTH by reducing the capacity of SCs to
produce increased amounts of RANKL and lower amounts of
OPG in response to PTH [11]. Thus T cell induction of CD40
signaling in SCs is a key mechanism by which T cells potentiate
the catabolic activity of cPTH. Interestingly, cPTH regulates the
CD40L/CD40 mediated cross-talk between T cells and SCs, not
by regulating CD40L expression in T cells, but rather by
increasing the expression of CD40 in SCs. The stimulatory
activity of cPTH on SC CD40 expression is silenced in T cell
deficient mice, indicating that cPTH regulates the expression of
CD40 in SCs via a T cell-dependent mechanism yet to be
discovered [11]. The current experiments revealed that whereas
cPTH treatment increased CD40 expression in SCs derived from
the BM of control mice, it failed to upregulate CD40 in SC from
PPR
T cells 2/2 mice. Furthermore, similar to SCs from mice
lacking T cells, CD40L,or CD40 [11], the SC from PPR
Tc e l l s2/2
mice exhibited altered RANKL/OPG production and blunted
osteoclastogenic response to cPTH. These findings indicate that T
cell expressed PPR mediates the osteoclastogenic response of SCs to
cPTH by upregulating CD40 expression, thereby promoting
CD40L/CD40 signaling. The relevance of CD40L/CD40 signal-
ing to SCs response to PTH was further demonstrated by finding
that PTH activation of ERK2 in SCs was increased when SCs were
pretreated with soluble CD40L.
It could be argued that disruption of PPR signaling in T cells
does not specifically abrogates the capacity of SCs to support PTH
induced osteoclastogenesis, but rather blunts the SC response to all
osteoclastogenic factors. The results of the ovx experiments
described herein suggest that this is not the case. In fact, we
found that ovx causes similar bone loss in PPR
Tcells 2/2 and
control mice treated with vehicle. Since one key mechanism by
which ovx causes bone loss is by increasing SC osteoclastogenic
activity [37], the data indicate that deletion of PPR in T cells does
not block the increase in SC osteoclastogenic activity induced by
ovx. The data rather suggest that deletion of PPR in T cells
specifically blocks the SC osteoclastogenic response to PTH.
While PPR signaling in T cells regulates SC osteoclastogenic
activity, silencing of T cell PPR did not alter the capacity of SCs to
differentiate into OBs. This may suggest that the SCs which
support OC formation are not the same cells that differentiate into
OBs, the cells that form osteoid and mineralize it, a hypothesis
recently proposed by others [38]. Indeed osteoclastogenic SCs
express intercellular adhesion molecule-1 (ICAM-1) which is
necessary for binding to OC precursors [39], while matrix-
producing osteoblastic cells are ICAM-1 negative [40].
TNF is a potent osteoclastogenic cytokine which plays a pivotal
role in the bone loss induced by inflammation, periodontal bone
disease and estrogen deficiency [41]. Interestingly, our data show
that cPTH fails to induce bone loss and stimulate bone resorption
in TNF 2/2 mice and in nude mice adoptively transferred with
TNF2/2 T cells. The effects of cPTH were however restored
when nude mice were adoptively transferred with WT T cells
demonstrating that T cell produced TNF plays a key role in
Figure 4. Regulation of SC CD40 expression and T cell TNF
production. A Effect of in vitro TNF treatment on CD40 mRNA
expression by SCs. B Effect of in vivo cPTH treatment on CD40 mRNA
levels in SCs from WT and TNF2/2 mice. C Effect of in vivo cPTH
treatment on TNF mRNA and TNF protein production by CD4+ cells
from PPR
T cells 2/2 and control mice. D Effect of in vivo cPTH treatment
on TNF mRNA and TNF protein production by CD8+ cells isolated from
PPR
T cells 2/2 and control mice. All data are expressed as mean 6 SEM.
*=p,0.05 and *=p,0.01 compared to the corresponding vehicle
group. n=6 mice per group.
doi:10.1371/journal.pone.0012290.g004
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production of TNF by CD4+ cells and CD8+ cells from control
but not PPR
Tcells2/2 mice. The diminished cPTH induced TNF
production by T cells from PPR
T cells 2/2 mice establishes TNF
production by T cells as a downstream effector of cPTH
stimulation of PPR in T cells. These findings may help explaining
the cause of increased levels of circulating TNF in patients affected
by PHP [42].
TNF is known to stimulate bone resorption and causes bone loss
bypotentiatingtheosteoclastogenicactivityofRANKLproduced in
the BM microenvironment [43,44] and by increasing the
production of RANKL by SCs and OBs via activation of the NFkB
and JNK signaling pathways [45]. A novel finding is that similar to
the silencing of PPR, deletion of TNF in T cells decreases the ability
of cPTH to upregulate CD40 expression, and to increase the
RANKL/OPG ratio in SCs. Further attesting to the capacity of
Figure 5. Effects of cPTH on bone structure and turnover in TNF 2/2 mice. A mCT analysis of femoral Co.Th. B mCT analysis of femoral Co.Vo.
C mCT analysis of BV/TV. D Serum CTX levels. E Serum OCN levels. F–J Histomorphometric analysis of femoral trabecular bone. F: percentage of bone
surface covered by osteoclasts (Oc.S/BS). G: number of osteoclasts per mm bone surface (N.Oc/BS). H: Bone formation rate (BFR). I: Percentage of
bone surface covered by osteoblasts (Ob.S/BS). J: Number of osteoblasts per mm bone surface (N.Ob/BS). K–L mRNA levels of RANKL and OPG in SCs
from WT and TNF2/2 mice treated in vivo with vehicle or cPTH. *=p,0.05 compared to the corresponding vehicle group. n=9–15 mice per group.
Data are Means + SEM.
doi:10.1371/journal.pone.0012290.g005
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stimulation of SCs by TNF increased the SC expression of CD40
mRNA. PPR signaling in T cells thus mediates cPTH induced
CD40 expression in SCs by controlling TNF production by T cells.
Collectively, our data reveal that the effects of cPTH on bone
are the result of a mechanism that involves PPR activation and
TNF production in T cells. T cell produced TNF stimulates bone
resorption directly by potentiating the sensitivity of maturing OCs
to RANKL. In addition, TNF enhances CD40L/CD40 signaling
from T cells to SCs by upregulating CD40 expression, an effect
resulting in the increased capacity of SCs to support OC
formation. Thus, a complex cross-talk between T cells and the
osteoclastogenic machinery of the BM is central for the bone
catabolic activity of cPTH.
Our study provide a new insight into the signaling integration
between cells of the immune system and bone cells and the impact
of such cellular interaction on bone loss. Understanding the PPR
signaling in T cells and the cross-talk between T cells and SCs may
thus yield novel therapeutic strategies for PTH-induced bone
disease and may help understand the pathophysiology of bone loss
associated with immune disorders.
Materials and Methods
Animals
All animal procedures were approved by the Institutional
Animal Care and Use Committee of Emory University (IACUC
Figure 6. Effects of cPTH treatment in mice lacking T cell TNF
production. A mCT analysis of femoral Co.Th. B mCT analysis of femoral
Co.Vo. C mCT analysis of BV/TV. D Serum CTX levels. E Serum OCN
levels. *=p,0.05, **=p,0.01 and ***=p,0.001 compared to the
corresponding vehicle treated group. n=10–17 mice per group. Data
are Means + SEM.
doi:10.1371/journal.pone.0012290.g006
Figure 7. Schematic representation of the role of T cell PPR in
cPTH stimulation of OC formation. PTH binding to PPR in T cells
stimulates the production of TNF. This cytokine increases CD40
expression by SCs. Binding of CD40 by T cell expressed CD40L increases
SC sensitivity to PTH resulting in enhanced SC production of RANKL and
diminished secretion of OPG in response to PTH. T cell produced TNF
further stimulates OC formation through its direct effects on maturing
OC precursors. The red arrows represent the main modifications
induced by activation of PPR signaling in T cells.
doi:10.1371/journal.pone.0012290.g007
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in male or female mice of 16 weeks of age. C57BL/6 WT and
TNF 2/2 mice were purchased from The Jackson Laboratory
(Bar Harbor, Maine). All mice were maintained under non-specific
pathogen free conditions and fed sterilized food and autoclaved
water ad libitum.
In vivo PTH infusion
80 mg/kg/day of hPTH1-34 (Bachem California Inc., Tor-
rance, CA) or vehicle were delivered for 2 weeks by implanting
ALZET osmotic pump model-1002 (DURECT corporation,
Cupertino, CA) with a delivery rate of 0.25 ml/hr, as described
[11].
Generation of mice with T cell-specific PPR silencing
Homozygous floxed, PPR (PPR
fl/fl) mice were generated as
described previously [25]. Mice with T cell-specific PPR gene
disruption (PPR
T cells 2/2 mice) were generated by crossing
homozygous PPR
fl/fl mice with Cre transgenic mice expressing Cre
under the T cell specific promoter Lck. Disruption of the PPR
gene was confirmed by PCR analysis of genomic DNA using
forward and reverse primers specific for sequences upstream and
downstream respectively, of the floxed exon E1. Disruption of the
PPR gene was also confirmed by real time RT-PCR analysis of
PPR mRNA using a forward primer specific for a sequence inside
the floxed exon E1 and a reverse primer specific for a sequence
inside exon E3.
T cell Transfer
Nude mice were subjected to adoptive transfer of WT and
TNF2/2 spleen T cells via tail-vein injection of 2610
6 T cells
purified by positive immuno-magnetic selection using MACS
Microbeads (Miltenyi Biotec, Auburn, CA) coupled to non-
activating anti-CD90 (Thy1.2), antibodies, as previously described
[11,19,29]. T cells were transferred into nude mice 2 weeks before
treatment to allow for engraftment and peripheral expansion of
the transferred T cells, as well as the recovery of SC function.
Successful T cell engraftment was confirmed by flow cytometry of
splenocytes harvested at sacrifice as described previously
[11,19,29].
Stromal cells purification
BM SCs were purified as described previously [11]. Briefly, BM
was collected from long bones by centrifugation and cultured for
5–7 days. After discarding the non adherent cells, adherent BMMs
were eliminated by positive immunoselection by MACS Microbe-
ads (Miltenyi Biotec, Auburn, CA) coupled to anti-CD11c
antibody. This marker is expressed on non adherent DCs and
adherent BMMs [46]. The remaining adherent cells were SCs.
Cell purity was verified by histochemical staining for nonspecific
esterase, a marker for cells of the monocytic/macrophage lineage.
Purified SCs were .95% nonspecific esterase negative. When
cultured in the presence of 50 mg/ml of ascorbic acid and 5 mM
b-glycerophosphate to induce differentiation toward the osteo-
blastic lineage, SCs were .95% positive for alkaline phosphatase
(ALP), a marker of differentiated BM SCs.
BMMs and T cells purification and culture
BMMs and T cells were purified from the BM and spleen by
positive immunoselection using MACS Microbeads (Miltenyi
Biotech,) coupled to anti-CD11b, anti CD90, or anti CD4 and
anti CD8 antibodies, as described [11,19]. Cell purity was verified
to be .90% by FACS.
In vitro OC generation
BM or cultures of BMMs, SCs and T cells were cultured for 7
days in the presence of human PTH 1–34 (1 nM) to induce OC
formation as described [11,19]. The cultures were then fixed and
stained for tartrate-resistant acid phosphatase (TRAP). TRAP
positive cells with $3 nuclei were scored as OCs.
mCT measurements of cortical and trabecular bone
mCT scanning and analysis was performed as reported
previously [19] using a Scanco mCT-40 scanner (Scanco Medical,
Bassersdorf, Switzerland). Bones were scanned at a resolution of
12 mm, tomographic images were obtained at conditions of 70 KV
and 114 mA by collecting 500 projections. Trabecular bone
volume (BV/TV) was measured in the epiphysis of the distal
femurs harvested from mice sacrificed at 18 weeks of age. This
region of interest was selected because at the metaphysis of 18
week old C57BL/6 mice contains little trabecular bone, a feature
which prevents the detection of cPTH induced trabecular bone
loss. Cortical bone volume and cortical thickness were determined
by analyzing 80 slices at the mid –diaphysis of the femurs as
described [11,19].
Quantitative bone histomorphometry
Bone histomorphometry analysis was performed at the
University of Alabama at Birmingham, Center for Metabolic
Bone Disease, Histomorphometry and Molecular Analysis Core
Laboratory by using Bioquant Image Analysis software (R&M
Biometrics, Nashville, TN), as described [11,19]. The measure-
ments, terminology and units used for histomorphometric
analysis, were those recommended by the Nomenclature
Committee of the American Society of Bone and Mineral
Research [47]. Longitudinal sections (5 mm thick) were cut from
Methyl Methacrylate (MMA) plastic embedded blocks along the
frontal plane, using a Leica 2265 microtome, and stained with
Goldner’s Trichrome stain for the static measurements.
Additional sections were cut at 10 mm, and left unstained for
dynamic (fluorescent) measurements. For the analysis of
trabecular bone, measurements were obtained in an area of
the distal epiphysis of the femur spanning from 75 mmf r o mt h e
growth plate to the endocortical edge of the epiphysis, as
previously described [48]. N.Ob/BS (the number of OBs per
mm bone surface), ObS/BS (the percentage of bone surface
covered by OBs), N.OC/BS (the number of OCs per mm bone
surface), OcS/BS (the percentage of BS occupied by OCs) and
bone formation rate (BFR) were measured.
Measurement of serum markers of bone turnover
Serum markers of bone turnover have been measured as
described previously [11,19]. Serum CTX, a marker of bone
resorption, was measured by a rodent specific ELISA assay
(Immunodiagnostic Systems, Scottsdale AZ). Serum osteocalcin
(OCN), a specific marker for bone formation, was measured using
Rat-MID
TM Osteocalcin ELISA kit (Nordic Bioscience Diagnos-
tics A/S, Herlev, Denmark).
Measurement of Serum Calcium, inorganic phosphate
and PTH
Serum calcium was measured by a colorimetric kit, Calcium
LiquiColor (Stanbio Laboratory, Boerne, TX). Serum levels of
endogenous PTH (1–84) were measured by ELISA using a
commercial kit (Immutopics, Inc., San Clemente, CA). Inorganic
phosphate was measured using Phosphorous Liqui-UV kits
(Standbio, Boerne, TX) as per manufacturer’s instructions.
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Splenic CD4+andCD8+T cells were purified from PPR
Tc e l l s2/2
and control mice treated with vehicle or cPTH for 2 weeks. Cells were
then cultured for 48 hours in plates coated with anti CD3 and anti
CD28 mAbs. TNF protein levels in the culture media were measured
by ELISA.
Real-Time RT-PCR
RANKL, OPG, CD40, and PPR mRNA were quantitated by
real-time PCR using a GeneAmp 7000 system (PE Biosystems) and
changes in relative gene expression between groups was calculated
using the 2–DDCT method with normalization to 18S rRNA as
previously described [49]. All primers for real time PCR were
designed by using Primer ExpressH Software v2.0 (PE Biosystems).
The sequence of primers used were: 59- ATTCGAACGTCT-
GCCCTATCA -39 (forward) and 5- GTCACCCGTGGTCAC-
CATG -39 (reverse) for 18 s, 59- CCTGATGAAAGGAGGGA-
GCA -39 (forward) and 59- TGGAATTCAGAATTGCCCGA -39
(reverse) for RANKL, and 59-CTTGGGTCTGTTGCTTG-
GTGA-39 (forward) and 59-GCCGCTTCCTTA CACACCAG-
39 (reverse) for OPG, 59-GCAGGAGCGGCAGGTGACAG-39
(forward) and 59-ACGCCGCAGCAAGACGACTC-39 (reverse)
for CD40, 59-ACAAAGGGTGGACGCCAGCA-39 (forward,
inside PPR exon E1) and 59-GCGGTCGCAGCGTCTGTA-
GG -39 (reverse, inside PPR exon E3), 59-TAATGCTCAGC-
GCCCCGT-39 (forward, upstream of PPR exon E1) and 59-AG-
CAGCAGACGCCGAGGCGA-39 (reverse, downstream of PPR
exon E1) for PPR. Amplification reactions were performed in
25 ml containing 0.5 mM of primers, dNTPs (0.2 mM each) in
PCR buffer and 0.03 U Taq polymerase along with SYBR-green
(Molecular Probes, Eugene, OR). Dissociation curves revealed a
single product in all cases.
Measurement of cAMP accumulation in T cells
cAMP was measured by radioimmunoassay as described
previously [19]. Briefly, CD4+ and CD8+ spleen T cells were
pre-treated with 1 mM IBMX (Sigma-Aldrich Biochemicals) for
1 hour, and then treated with either 50 nM PTH (1–34), or
vehicle for 10 minutes. cAMP was measured using a commercial
radioimmunoassay kit (PerkinElmer,Shelton CT) as per kit
instructions. Protein concentration was measured using the Bio-
Rad Dc (Bio-Rad) protein assay kit. cAMP concentrations were
expressed as pMol per mg protein.
Statistical Analysis
For each outcome, a two-way analysis-of-variance was applied
that included the main effects for animal strain and treatment plus
the statistical interaction between animal strain and treatment.
When the statistical interaction between animal strain and
treatment group was not statistically significant (P.0.05) nor
suggestive of an important interaction (P.0.10) p values for the
main effects tests were reported. When the statistical interaction
was statistically significant or suggestive of an important
interaction then t-tests were used to compare the differences
between the treatment means for each animal strain, applying the
Bonferroni correction for multiple comparisons. The response
studies shown in figure 4a were analyzed by one-way ANOVA.
Supporting Information
Figure S1 Serum calcium, inorganic phosphate, PTH, BMD
and T cell function in PPR
Tcells2/2 and control mice. A Serum
levels of calcium, inorganic phosphate and intact PTH at 6 weeks
of age. B Femoral BMD (Mean 6 SEM) at 6 weeks of age was
measured in anesthetized mice using a PIXImus2 bone densitom-
eter (GE Medical System, Lunar, Madison, WI). n=20 mice per
group. C Splenocytes were stained with APC anti-mouse CD4,
PerCP anti-mouse CD8, and analyzed by FACS. Data are
expressed as percentage. D Splenocytes were stimulated with plate
bound anti-CD3 and anti-CD28 mAbs for 24 hours, and stained
with FITC anti-mouse CD25. The cells were gated on CD4 and
CD8 and analyzed by FACS for expression of the activation
marker CD25. E CD90+ T cells were purified from the spleen of
untreated mice, stimulated with plate bound anti-CD3 and anti-
CD28 mAbs for 48 hours at the indicated doses and pulsed with
[3H] thymidine for the last 18 hours to assess their proliferation.
Data were analyzed by one-way ANOVA and expressed as CPM.
Found at: doi:10.1371/journal.pone.0012290.s001 (6.80 MB
TIF)
Figure S2 Effects of cPTH on bone structure and turnover in
female mice. A–C. Cortical and trabecular bone analysis mCT. D–
E Serum markers of bone turnover. CTX is a marker of
resorption. OCN is a marker of formation. F–I Histomorphomet-
ric analysis femoral trabecular bone. F: percentage of bone surface
covered by osteoclasts (OcS/BS). G: number of osteoclasts per mm
bone surface (N.Oc/BS). H: Percentage of bone surface covered
by osteoblasts (ObS/BS). I: Number of osteoblasts per mm bone
surface (N.Ob/BS). *=p,0.05, **=p,0.01 and ***=p,0.001
compared to the corresponding vehicle treated group. #=p,0.05
compared to the corresponding PPR
fl/fl mice. n=12–20 mice per
group for mCT and serum measurements. n=10 mice per group
for bone histomorphometry. Data are Means 6 SEM.
Found at: doi:10.1371/journal.pone.0012290.s002 (1.91 MB
TIF)
Figure S3 Effects of cPTH treatment on cortical and trabecular
bone volume in ovariectomized mice. PPR
fl/fl and PPR
T cells 2/2
mice were ovariectomized (ovx) at 16 weeks of age, treated with
vehicle or cPTH for 2 weeks, and sacrificed. Femoral BMD was
measured in vivo by DEXA at baseline and at 2 weeks. Femurs
were harvested and analyzed by mCT. A Femoral BMD. B cortical
thickness (Co.Th), C cortical volume (Co.Vo), and trabecular bone
volume (BV/TV). *=p,0.05 compared to the corresponding
vehicle treated group. #=p,0.05 compared to the corresponding
PPR
T cells 2/2 mice. Data are Means 6 SEM.
Found at: doi:10.1371/journal.pone.0012290.s003 (2.96 MB
TIF)
Figure S4 CFU-ALP and mineralization nodules formation in
PPR
Tcells2/2 and control mice. Top panel. Whole BM from
PPR
Tc e l l2/2 and control mice were cultured for 7 days to assess
the formation CFU-ALP. Bottom panel: Whole BM was cultured
for 14 days in a-MEM supplemented with 10% FBS, 1%
penicillin-streptomycin, and 10 mM of b-glycerophosphate for 2
weeks, and stained with AgNO3 by the Von Kossa method to
detect phosphate deposits in bone nodules. The panel shows
representative quadruplicate wells per group.
Found at: doi:10.1371/journal.pone.0012290.s004 (6.35 MB
TIF)
Figure S5 Effect of combined treatment with CD40L and PTH
on the SC level of phosphorylated ERK1/2. SCs were purified
from intact WT mice and plated at 250,000 cells/well on 12 well
plates. After an overnight incubation SCs were serum starved for
1 hour followed by treatment with recombinant CD40L (100 ng/
ml) for 5 min. PTH (5 nM) was then added and incubation
continued for 10 min. Cells were rinsed twice with ice-cold PBS
and collected in SDS lyses buffer. Equal amounts of sample lysates
were loaded and proteins were analyzed on 8% SDS polyacryl-
T Cell PTH Receptor
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nitrocellulose membrane and blotted and reblotted with antibodies
against phospho-ERK1/2 (P-ERK1/2), total-ERK1/2, and b-
actin and appropriate peroxidase-conjugated secondary antibod-
ies. Detection was performed using chemiluminescence and the
membranes were exposed to a film for 0.5 min. Densitometric
quantification of P-ERK2 and Total- ERK2 protein bands was
performed. Data are expressed as fold change compared to
vehicle.
Found at: doi:10.1371/journal.pone.0012290.s005 (3.87 MB TIF)
Acknowledgments
We are grateful to the University of Alabama at Birmingham, Center for
Metabolic Bone Disease-Histomorphometry and Molecular Analysis Core
Laboratory for the histomorphometric analysis presented herein.
Author Contributions
Conceived and designed the experiments: HT MNW HK RP. Performed
the experiments: HT BB JYL JA. Analyzed the data: HT BB RP.
Contributed reagents/materials/analysis tools: TK HK. Wrote the paper:
HT MNW RP.
References
1. Riggs BL, Melton LJ, 3rd (1986) Involutional osteoporosis. N Engl J Med 314:
1676–1686.
2. Grey AB, Stapleton JP, Evans MC, Reid IR (1996) Accelerated bone loss in post-
menopausal women with mild primary hyperparathyroidism. Clin Endocrinol
(Oxf) 44: 697–702.
3. Parisien M, Dempster DW, Shane E, Bilezikian JP (2001) Histomorphometric
analysis of bone in primary hyperparathyroidism. The parathyroids Basic and
clinical concepts. San Diego: Academic Press. pp 423–436.
4. Potts J (1998) Primary hyperparathyroidism. In: Avioli LV, Krane S, eds.
Metabolic Bone Diseases. #rd ed. San Diego: Academic Press. pp 411–442.
5. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, et al. (1989)
Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4: 283–291.
6. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13: 791–801.
7. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for
osteoporosis. N Engl J Med 357: 905–916.
8. Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, et al. (2005) Short-
term continuous infusion of human parathyroid hormone 1-34 fragment is
catabolic with decreased trabecular connectivity density accompanied by
hypercalcemia in C57BL/J6 mice. J Endocrinol 186: 549–557.
9. Lotinun S, Evans GL, Bronk JT, Bolander ME, Wronski TJ, et al. (2004)
Continuous parathyroid hormone induces cortical porosity in the rat: effects on
bone turnover and mechanical properties. J Bone Miner Res 19: 1165–1171.
10. Hock JM, Gera I (1992) Effects of continuous and intermittent administration
and inhibition of resorption on the anabolic response of bone to parathyroid
hormone. J Bone Miner Res 7: 65–72.
11. Gao Y, Wu X, Terauchi M, Li JY, Grassi F, et al. (2008) T cells potentiate PTH-
induced cortical bone loss through CD40L signaling. Cell Metab 8: 132–145.
12. Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, et al. (1999)
On the mechanism of cancellous bone preservation in postmenopausal women
with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84:
1562–1566.
13. Qin L, Raggatt LJ, Partridge NC (2004) Parathyroid hormone: a double-edged
sword for bone metabolism. Trends Endocrinol Metab 15: 60–65.
14. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, et al. (2001)
Activated parathyroid hormone/parathyroid hormone-related protein receptor
in osteoblastic cells differentially affects cortical and trabecular bone. J Clin
Invest 107: 277–286.
15. Lanske B, Amling M, Neff L, Guiducci J, Baron R, et al. (1999) Ablation of the
PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities
in bone development. J Clin Invest 104: 399–407.
16. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, et al. (2001) Catabolic effects
of continuous human PTH (1—38) in vivo is associated with sustained
stimulation of RANKL and inhibition of osteoprotegerin and gene-associated
bone formation. Endocrinology 142: 4047–4054.
17. Weir EC, Lowik CW, Paliwal I, Insogna KL (1996) Colony stimulating factor-1
plays a role in osteoclast formation and function in bone resorption induced by
parathyroid hormone and parathyroid hormone-related protein. J Bone Miner
Res 11: 1474–1481.
18. McCauley LK, Rosol TJ, Merryman JI, Capen CC (1992) Parathyroid
hormone-related protein binding to human T-cell lymphotropic virus type I-
infected lymphocytes. Endocrinology 130: 300–306.
19. Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, et al. (2009) T lymphocytes
amplify the anabolic activity of parathyroid hormone through Wnt10b signaling.
Cell Metab 10: 229–240.
20. Young N, Mikhalkevich N, Yan Y, Chen D, Zheng WP (2005) Differential
regulation of osteoblast activity by Th cell subsets mediated by parathyroid
hormone and IFN-gamma. J Immunol 175: 8287–8295.
21. Geffner ME, Bersch N, Cortez AB, Bailey RC, Golde DW (1995) Growth-
promoting actions of parathyroid hormone, adrenocorticotrophic hormone, and
thyroid-stimulating hormone: in vitro studies in normal and pygmy T-
lymphoblast cell lines. Pediatr Res 37: 507–511.
22. Stojceva-Taneva O, Fadda GZ, Smogorzewski M, Massry SG (1993)
Parathyroid hormone increases cytosolic calcium of thymocytes. Nephron 64:
592–599.
23. Ahuja SS, Zhao S, Bellido T, Plotkin LI, Jimenez F, et al. (2003) CD40 ligand
blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and
etoposide in osteoblasts and the osteocyte-like cell line murine long bone
osteocyte-Y4. Endocrinology 144: 1761–1769.
24. Hory BG, Roussanne MC, Rostand S, Bourdeau A, Drueke TB, et al. (2000)
Absence of response to human parathyroid hormone in athymic mice grafted
with human parathyroid adenoma, hyperplasia or parathyroid cells maintained
in culture. J Endocrinol Invest 23: 273–279.
25. Kobayashi T, Chung UI, Schipani E, Starbuck M, Karsenty G, et al. (2002)
PTHrP and Indian hedgehog control differentiation of growth plate chondro-
cytes at multiple steps. Development 129: 2977–2986.
26. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, et al. (2001) A critical
role for Dnmt1 and DNA methylation in T cell development, function, and
survival. Immunity 15: 763–774.
27. Brodt MD, Ellis CB, Silva MJ (1999) Growing C57Bl/6 mice increase whole
bone mechanical properties by increasing geometric and material properties.
J Bone Miner Res 14: 2159–2166.
28. Pacifici R (2010) T cells: Critical bone regulators in health and disease. Bone.
29. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, et al. (2001) Up-
regulation of TNF-producing T cells in the bone marrow: A key mechanism by
which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A
98: 13960–13965.
30. Eichinger A, Fiaschi-Taesch N, Massfelder T, Fritsch S, Barthelmebs M, et al.
(2002) Transcript expression of the tuberoinfundibular peptide (TIP)39/PTH2
receptor system and non-PTH1 receptor-mediated tonic effects of TIP39 and
other PTH2 receptor ligands in renal vessels. Endocrinology 143: 3036–3043.
31. Hoare SR, Clark JA, Usdin TB (2000) Molecular determinants of tuberoinfun-
dibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2
(PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/
PTH1 receptor binding selectivity. J Biol Chem 275: 27274–27283.
32. Usdin TB, Hoare SR, Wang T, Mezey E, Kowalak JA (1999) TIP39: a new
neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci 2:
941–943.
33. Divieti P, Geller AI, Suliman G, Juppner H, Bringhurst FR (2005) Receptors
specific for the carboxyl-terminal region of parathyroid hormone on bone-
derived cells: determinants of ligand binding and bioactivity. Endocrinology 146:
1863–1870.
34. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, et al. (2005) Chronic elevation of
parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a
novel mechanism for hormonal control of osteoblastogenesis. Endocrinology
146: 4577–4583.
35. O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, et al. (2008) Control
of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS
ONE 3: e2942.
36. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, et al. (2005) Regulation
of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102:
3324–3329.
37. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R (1996) Estrogen
deficiency increases the ability of stromal cells to support murine osteoclastogen-
esis via an interleukin-1and tumor necrosis factor- mediated stimulation of
macrophage colony-stimulating factor production. J Biol Chem 271:
28890–28897.
38. Galli C, Fu Q, Wang W, Olsen BR, Manolagas SC, et al. (2009) Commitment to
the osteoblast lineage is not required for RANKL gene expression. J Biol Chem
284: 12654–12662.
39. Tanaka Y, Maruo A, Fujii K, Nomi M, Nakamura T, et al. (2000) Intercellular
adhesion molecule 1 discriminates functionally different populations of human
osteoblasts: characteristic involvement of cell cycle regulators. J Bone Miner Res
15: 1912–1923.
40. Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, et al.
(2002) The bone lining cell: its role in cleaning Howship’s lacunae and initiating
bone formation. J Bone Miner Res 17: 77–90.
41. Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an
inflammatory tale. J Clin Invest 116: 1186–1194.
42. Grey A, Mitnick MA, Shapses S, Ellison A, Gundeberg C, et al. (1996)
Circulating levels of Intreleukin-6 and tumor necrosis factor a are elevated in
primary hyperparathyroidism and correlate with markers of bone resorption.
JClinEndoMetab 81: 3450–3468.
T Cell PTH Receptor
PLoS ONE | www.plosone.org 13 August 2010 | Volume 5 | Issue 8 | e1229043. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, et al. (2000)
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-
alpha. J Clin Invest 106: 1229–1237.
44. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, et al. (2000) TNF-alpha
induces osteoclastogenesis by direct stimulation of macrophages exposed to
permissive levels of RANK ligand. J Clin Invest 106: 1481–1488.
45. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology
142: 5050–5055.
46. Corbi AL, Lopez-Rodriguez C (1997) CD11c integrin gene promoter activity
during myeloid differentiation. Leuk Lymphoma 25: 415–425.
47. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. (1987)
Bone histomorphometry: standardization of nomenclature, symbols, and units.
Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone
Miner Res 2: 595–610.
48. Grassi F, Tell G, Robbie-Ryan M, Gao Y, Terauchi M, et al. (2007) Oxidative
stress causes bone loss in estrogen-deficient mice through enhanced bone
marrow dendritic cell activation. Proc Natl Acad Sci U S A 104: 15087–15092.
49. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, et al. (2003) Estrogen
deficiency induces bone loss by increasing T cell proliferation and lifespan
through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A
100: 10405–10410.
T Cell PTH Receptor
PLoS ONE | www.plosone.org 14 August 2010 | Volume 5 | Issue 8 | e12290